JAAD supplemental material - Response to systemic therapies in granulomatous cheilitis: retrospective multicenter series of 61 patients
Description
Supplemental Material Supplemental material Mendeley Supplemental Table 1. Case review of systemic therapies in CG. Mendeley Supplemental Table 2. Modalities and responses to systemic therapies in the whole study population and by underlying disease. Response rates (proportion of responders including CR and PR), CR rates, duration of therapy, duration of response and relapse rates were assessed for each systemic therapy modality. Only therapies that had been assessed in at least 3 patients are provided. CFZ, clofazimine; HCQ, hydroxychloroquine; CS, corticosteroids; MTZ, metronidazole; IFX, infliximab; ADA, adalimumab; CR, complete responses; NA, not applicable. Mendeley Supplemental Figure 1. Responses to systemic therapies in patients with Miescher’s macrocheilitis (n=38). Best response (non-response [NR], complete response [CR] or partial response [PR]) is indicated. CFZ, clofazimine; HCQ, hydroxychloroquine; CS, corticosteroids; MTZ, metronidazole; MTX, methotrexate; THD, thalidomide; SZP, salazopyrine; IFX, infliximab; ADA, adalimumab; RITUX, rituximab Mendeley Supplemental Figure 2. Responses to systemic therapies in patients with Melkersson-Rosenthal syndrome (n=9, panel A), Crohn’s disease (n=10, panel B) and sarcoidosis (n=4, panel C). Best response (non-response [NR], complete response [CR] or partial response [PR]) is indicated. CFZ, clofazimine; HCQ, hydroxychloroquine; CS, corticosteroids; MTZ, metronidazole; MTX, methotrexate; THD, thalidomide; AZA, azathioprine; ASA, 5-aminosalicylic acid; CYS, cyclosporine; IFX, infliximab; ADA, adalimumab; UST, ustekinumab; GOLI, golimumab; VEDO, vedolizumab. Mendeley Supplemental Figure 3. Cumulative proportion of complete response over time. The Kaplan-Meier cumulative incidence curve was constructed to assess the proportion of patients with complete resolution of GC over time. (XL-Stat-Life, Addinsoft, Paris, France).